Another issue for investors is that Eli Lilly adjusted its guidance for the year, now projecting its adjusted EPS to fall ...

Aristotle Large Cap Growth Strategy highlighted stocks like Eli Lilly and Company (NYSE:LLY) in the third quarter 2024 ...

Eli Lilly (NYSE:LLY) shares were on track to snap six straight sessions of losses on Thursday, as the stock rose 1.9% at $790 ...

Indianapolis-based pharmaceutical giant Eli Lilly and Company has purchased 30.9 acres of vacant land to the north and to the ...

Here's why Eli Lilly is a no-brainer stock to buy on the dip ... Should investors be worried about weakness in the company's ...

Dave Ricks, the CEO of Indianapolis-based Eli Lilly and Co., is the recipient of the 2024 August M. Watanabe Life Sciences ...

It's shaping up to be a tough period for Eli Lilly and Company , which a week ago released some disappointing third-quarter ...

Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...

Eli Lilly and Company has shown rapid growth with significant revenue increases. Click here to find out why I've decided to ...

Eli Lilly will report third-quarter earnings Wednesday morning. Investor focus remains on the production and sales of its ...